cyclophosphamide

Summary

Summary: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active ALDOPHOSPHAMIDE. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Top Publications

  1. ncbi Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 24:4236-44. 2006
  2. pmc Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    Nathalie A Johnson
    British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 30:3452-9. 2012
  3. ncbi Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    Tina Marie Green
    Department of Pathology, Odense University Hospital, J B Winsløws Vej 15, DK 5000 Odense C, Denmark
    J Clin Oncol 30:3460-7. 2012
  4. pmc Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
    C Marcela Diaz-Montero
    Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA
    Cancer Immunol Immunother 58:49-59. 2009
  5. pmc Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective
    Dung T Le
    The Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Res 72:3439-44. 2012
  6. ncbi Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
    M Hallek
    Department I of Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany
    Lancet 376:1164-74. 2010
  7. pmc Rituximab versus cyclophosphamide for ANCA-associated vasculitis
    John H Stone
    Massachusetts General Hospital, Boston, USA
    N Engl J Med 363:221-32. 2010
  8. ncbi Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
    Steffen Walter
    Immatics Biotechnologies GmbH, Tubingen, Germany
    Nat Med 18:1254-61. 2012
  9. ncbi Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
    Priya Rastogi
    University of Pittsburgh Cancer Institute Magee Womens Hospital, 300 Halket St, Room 3524, Pittsburgh, PA 15213, USA
    J Clin Oncol 26:778-85. 2008
  10. ncbi Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18
    B Fisher
    Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Shadyside Hospital, PA, USA
    J Clin Oncol 15:2483-93. 1997

Detail Information

Publications303 found, 100 shown here

  1. ncbi Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer
    Kenneth R Hess
    Department of Biostatistics and Applied Mathematics, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 24:4236-44. 2006
    We developed a multigene predictor of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil-doxorubicin-cyclophosphamide (T/FAC) chemotherapy and assessed its predictive accuracy on independent cases.
  2. pmc Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    Nathalie A Johnson
    British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 30:3452-9. 2012
    Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)...
  3. ncbi Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
    Tina Marie Green
    Department of Pathology, Odense University Hospital, J B Winsløws Vej 15, DK 5000 Odense C, Denmark
    J Clin Oncol 30:3460-7. 2012
    ..DHLs are characterized by poor outcome. We tested whether DLBCLs with high expression of MYC protein and BCL2 protein share the clinical features and poor prognosis of DHLs...
  4. pmc Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy
    C Marcela Diaz-Montero
    Department of Surgery, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA
    Cancer Immunol Immunother 58:49-59. 2009
    ..b>Cyclophosphamide (CTX) has also been shown in non-tumor bearing animals to cause transient surges in MDSC...
  5. pmc Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective
    Dung T Le
    The Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Res 72:3439-44. 2012
    ..In addition, specific agents that target Tregs are currently unavailable. Cyclophosphamide has emerged as a clinically feasible agent that can suppress Tregs and allow more effective induction of ..
  6. ncbi Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
    M Hallek
    Department I of Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany
    Lancet 376:1164-74. 2010
    ..several phase 2 trials, we investigated whether the addition of the monoclonal antibody rituximab to first-line chemotherapy with fludarabine and cyclophosphamide would improve the outcome of patients with chronic lymphocytic leukaemia.
  7. pmc Rituximab versus cyclophosphamide for ANCA-associated vasculitis
    John H Stone
    Massachusetts General Hospital, Boston, USA
    N Engl J Med 363:221-32. 2010
    b>Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis for 40 years...
  8. ncbi Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
    Steffen Walter
    Immatics Biotechnologies GmbH, Tubingen, Germany
    Nat Med 18:1254-61. 2012
    ..The randomized phase 2 trial showed that a single dose of cyclophosphamide reduced the number of T(reg) cells and confirmed that immune responses to multiple TUMAPs were associated ..
  9. ncbi Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
    Priya Rastogi
    University of Pittsburgh Cancer Institute Magee Womens Hospital, 300 Halket St, Room 3524, Pittsburgh, PA 15213, USA
    J Clin Oncol 26:778-85. 2008
    ..and Bowel Project (NSABP) Protocol B-18 was designed to determine whether four cycles of doxorubicin and cyclophosphamide (AC) administered preoperatively improved breast cancer disease-free survival (DFS) and overall survival (OS) ..
  10. ncbi Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18
    B Fisher
    Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Shadyside Hospital, PA, USA
    J Clin Oncol 15:2483-93. 1997
    To determine whether preoperative doxorubicin and cyclophosphamide (AC) permits more lumpectomies to be performed and decreases the incidence of positive nodes in women with primary breast cancer.
  11. ncbi A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy
    Vivekanand Jha
    Department of Nephrology, Postgraduate Institute of Medical Education and Research, Chandigarh 160 012 India
    J Am Soc Nephrol 18:1899-904. 2007
    ..This study compared the effect of a 6-mo course of alternating prednisolone and cyclophosphamide with supportive treatment in adults with nephrotic syndrome caused by IMN on doubling of serum creatinine, ..
  12. ncbi Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial
    Heikki Joensuu
    Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland
    J Clin Oncol 27:5685-92. 2009
    ..Efficacy and long-term safety of a short course of adjuvant trastuzumab administered concomitantly with chemotherapy for human epidermal growth factor receptor 2 (HER2) -positive cancer are unknown...
  13. pmc Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis
    Gerald B Appel
    Department of Nephrology, Columbia University, New York, New York, USA
    J Am Soc Nephrol 20:1103-12. 2009
    Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis, but these therapies have not been compared in an international randomized, ..
  14. ncbi CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma
    Bertrand Coiffier
    Hospices Civils de Lyon and the Université Claude Bernard, Lyons, France
    N Engl J Med 346:235-42. 2002
    The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)...
  15. ncbi Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
    Michael Pfreundschuh
    Internal Medicine, Saarland University Medical School, Saarland University, Homburg, Germany
    Lancet Oncol 9:105-16. 2008
    b>Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) is used to treat patients with non-Hodgkin lymphoma...
  16. ncbi Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results
    M J Piccart
    European Organization for Research and Treatment of Cancer EORTC Gynecological Cancer Cooperative Group, EORTC Data Center, Brussels, Belgium
    J Natl Cancer Inst 92:699-708. 2000
    ..for patients with advanced ovarian cancer on the paclitaxel-cisplatin regimen than for those on a standard cyclophosphamide-cisplatin regimen...
  17. ncbi Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte
    P Feugier
    Hematology Department, Centre Hospitalier Universitaire de Brabois, 54500 Vandoeuvre les Nancy, France
    J Clin Oncol 23:4117-26. 2005
    ..the long-term outcome of patients included in the Lymphome Non Hodgkinien study 98-5 (LNH98-5) comparing cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) in elderly patients with ..
  18. pmc Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus
    Vincenzo Cerullo
    Cancer Gene Therapy Group, Transplantation Laboratory, Haartman Institute and Finnish Institute of Molecular Medicine, University of Helsinki, Helsinki, Finland
    Mol Ther 19:1737-46. 2011
    ..to and progressing after conventional therapies were treated with three different regimens of low-dose cyclophosphamide (CP) in combination with oncolytic adenovirus...
  19. ncbi Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome
    Yingzi Ge
    Division of Translational Immunology, Tumor Immunology Program, German Cancer Research Center DKFZ, National Center for Tumor Diseases NCT, INF 460, 69120, Heidelberg, Germany
    Cancer Immunol Immunother 61:353-62. 2012
    ..Several preclinical and clinical observations suggest that Treg can be depleted by cyclophosphamide. Over a period of 3 months, we investigated the effect of metronomic low-dose cyclophosphamide on Treg ..
  20. ncbi Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups
    Michael Untch
    Helios Klinikum Berlin Buch, Schwanebecker Chaussee 50, 13125 Berlin, Germany
    J Clin Oncol 29:3351-7. 2011
    To evaluate efficacy and safety of epirubicin and cyclophosphamide followed by paclitaxel and trastuzumab as neoadjuvant treatment in patients with human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer.
  21. ncbi Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms
    Mikayel Mkrtichyan
    Cancer Vaccine Section, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Eur J Immunol 41:2977-86. 2011
    ..Here, we find that using an anti-PD-1 antibody (CT-011) with Treg-cell depletion by low-dose cyclophosphamide (CPM), combined with a tumor vaccine, induces synergistic antigen-specific immune responses and reveals novel ..
  22. pmc Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
    J Bray
    Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle upon Tyne, UK
    Br J Cancer 102:1003-9. 2010
    Doxorubicin and cyclophosphamide (AC) therapy is an effective treatment for early-stage breast cancer. Doxorubicin is a substrate for ABCB1 and SLC22A16 transporters...
  23. ncbi The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
    Laurie H Sehn
    Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada
    Blood 109:1857-61. 2007
    ..In the era of R-CHOP treatment, the R-IPI is a clinically useful prognostic index that may help guide treatment planning and interpretation of clinical trials...
  24. ncbi Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
    D J Slamon
    Division of Hematology and Oncology, UCLA School of Medicine, Los Angeles, Calif 90095 1678, USA
    N Engl J Med 344:783-92. 2001
    ..The HER2 gene, which encodes the growth factor receptor HER2, is amplified and HER2 is overexpressed in 25 to 30 percent of breast cancers, increasing the aggressiveness of the tumor...
  25. ncbi Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis
    Rachel B Jones
    Vasculitis and Lupus Clinic, Renal Unit, Addenbrooke s Hospital, Cambridge, United Kingdom
    N Engl J Med 363:211-20. 2010
    b>Cyclophosphamide induction regimens for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis are effective in 70 to 90% of patients, but they are associated with high rates of death and adverse events...
  26. ncbi The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide
    F A Houssiau
    Rheumatology Department, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Avenue Hippocrate, 10, B 1200 Bruxelles, Belgium
    Ann Rheum Dis 69:61-4. 2010
    ..of the Euro-Lupus Nephritis Trial (ELNT), a randomised prospective trial comparing low-dose (LD) and high-dose (HD) intravenous (IV) cyclophosphamide (CY) followed by azathioprine (AZA) as treatment for proliferative lupus nephritis.
  27. ncbi Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial
    Joseph Ragaz
    McGill University Health Center, Royal Victoria Hospital, 687 Pine Ave, Montreal, PQ, Canada H3A 1A1
    J Natl Cancer Inst 97:116-26. 2005
    ..We report the analysis of data from the 20-year follow-up...
  28. ncbi Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma
    Shaji Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:4375-82. 2012
    Combinations of bortezomib (V) and dexamethasone (D) with either lenalidomide (R) or cyclophosphamide (C) have shown significant efficacy...
  29. pmc Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation
    Gareth J Morgan
    Institute of Cancer Research, Royal Marsden Hospital, London, United Kingdom
    Blood 118:1231-8. 2011
    As part of the randomized MRC Myeloma IX trial, we compared an attenuated regimen of cyclophosphamide, thalidomide, and dexamethasone (CTDa; n = 426) with melphalan and prednisolone (MP; n = 423) in patients with newly diagnosed multiple ..
  30. ncbi Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01
    Francesco D'Amore
    Dept Hematology, Aarhus University Hospital, DK 8000 Aarhus C, Denmark
    J Clin Oncol 30:3093-9. 2012
    ..This is the final report, with a 5-year median follow-up, of the NLG-T-01 study...
  31. pmc Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study
    S K Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1350-6. 2010
    ..gov: NCT00507442) was conducted to determine the maximum tolerated dose (MTD) of cyclophosphamide in combination with bortezomib, dexamethasone and lenalidomide (VDCR) and to assess the safety and efficacy ..
  32. ncbi Immunomodulatory effects of cyclophosphamide and implementations for vaccine design
    Antonella Sistigu
    INSERM, U1015, 94805 Villejuif, France
    Semin Immunopathol 33:369-83. 2011
    ..Since 1959, alkylating agents, such as the lead compound cyclophosphamide (CTX), have always been conceived, at high dosages, as potent cytotoxic and lymphoablative drugs, ..
  33. pmc Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response
    Anne M Ercolini
    Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    J Exp Med 201:1591-602. 2005
    ..However, treatment of neu-N mice with vaccine and cyclophosphamide-containing chemotherapy resulted in tumor protection in a proportion of mice...
  34. ncbi HER2 and response to paclitaxel in node-positive breast cancer
    Daniel F Hayes
    Breast Oncology Program, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109, USA
    N Engl J Med 357:1496-506. 2007
    ..We hypothesized that HER2 positivity predicts a benefit from adjuvant doxorubicin doses above standard levels, from the addition of paclitaxel after adjuvant chemotherapy with doxorubicin plus cyclophosphamide, or from both.
  35. ncbi Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902
    J A van der Hage
    European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium
    J Clin Oncol 19:4224-37. 2001
    ....
  36. ncbi Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Edward H Romond
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    N Engl J Med 353:1673-84. 2005
    ..We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer...
  37. pmc Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer
    Adel Tabchy
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Clin Cancer Res 16:5351-61. 2010
    ..of pathologic complete response (pCR) to preoperative weekly paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide (T/FAC) chemotherapy, and assessed if DLDA-30 also predicts increased sensitivity to FAC-only chemotherapy...
  38. ncbi Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
    Ellen M Ginzler
    Division of Rheumatology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
    N Engl J Med 353:2219-28. 2005
    ..Since anecdotal series and small, prospective, controlled trials suggest that mycophenolate mofetil may be effective for treating lupus nephritis, larger trials are desirable...
  39. ncbi Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer
    Silvia Dellapasqua
    Medical Senology Research Unit and Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy
    J Clin Oncol 26:4899-905. 2008
    ..Metronomic chemotherapy has shown efficacy in patients with metastatic breast cancer. When used in association with targeted antiangiogenic drugs, it was more active than metronomic therapy alone in preclinical and clinical studies...
  40. pmc Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial
    Frédéric A Houssiau
    Rheumatology Department, Cliniques Universitaires Saint Luc, Universite Catholique de Louvain, Saint Luc University Hospital, Brussels 1200, Belgium
    Ann Rheum Dis 69:2083-9. 2010
    ..This investigator-initiated randomised trial tested whether mycophenolate mofetil (MMF) was superior to azathioprine (AZA) as maintenance treatment...
  41. pmc Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model
    Maria A Thomas
    Department of Molecular Microbiology and Immunology, Saint Louis University School of Medicine, St Louis, Missouri 63104, USA
    Mol Ther 16:1665-73. 2008
    ..We first determined that cyclophosphamide (CP) is a potent immunosuppressive agent in the Syrian hamster and that CP alone had no effect on tumor ..
  42. pmc Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
    Bertrand Coiffier
    Hospices Civils de Lyon and Université Lyon 1, Lyon, France
    Blood 116:2040-5. 2010
    We report the outcome of patients included in the LNH-98.5 study, which compared cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) therapy in 399 patients with diffuse large B-cell lymphoma (..
  43. pmc Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses
    Giulia Fulci
    Dardinger Center for Neuro oncology and Neurosciences, Department of Neurological Surgery, James Cancer Hospital and Solove Research Institute, Ohio State University Medical Center, Columbus, OH 43210, USA
    Proc Natl Acad Sci U S A 103:12873-8. 2006
    ..have brain tumors and are treated with a herpes simplex virus (HSV)-derived OV live significantly longer when cyclophosphamide (CPA) is preadministered. Here, we explore the mechanisms behind this finding...
  44. ncbi CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
    Michael Pfreundschuh
    University Clinic of Saarland, Homburg, Germany
    Lancet Oncol 7:379-91. 2006
    The role of rituximab in combination with different CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy regimens in young patients with good-prognosis diffuse large-B-cell lymphoma remains to be defined...
  45. pmc Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide
    R M Myers
    Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Clin Pharmacol Ther 82:700-10. 2007
    ..Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide, in Patients with Recurrent or Refractory Multiple Myeloma...
  46. ncbi Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma
    Robert Marcus
    Department of Haematology, Addenbrooke s Hospital, Cambridge, UK
    J Clin Oncol 26:4579-86. 2008
    ..outcome of patients with previously untreated follicular lymphoma (FL) needing therapy, after treatment with cyclophosphamide, vincristine and prednisone (CVP) versus CVP plus rituximab (R-CVP) and to evaluate the predictive value of ..
  47. ncbi Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial
    Herve Bonnefoi
    Geneva University Hospital, Geneva, Switzerland
    Lancet Oncol 8:1071-8. 2007
    ..The aim of this study was to confirm the validity of these gene-expression signatures in a large series of patients with oestrogen-receptor-negative breast tumours who were treated in a phase III neoadjuvant clinical trial...
  48. ncbi Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide
    Frédéric A Houssiau
    Cliniques Universitaires St Luc, Universite Catholique de Louvain, Brussels, Belgium
    Arthritis Rheum 46:2121-31. 2002
    ..of systemic lupus erythematosus (SLE) that is usually treated with an extended course of intravenous (IV) cyclophosphamide (CYC)...
  49. pmc 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study
    Gianni Bonadonna
    Istituto Nazionale Tumori, 20133 Milan, Italy
    BMJ 330:217. 2005
    To assess the long term effectiveness of adjuvant treatment with cyclophosphamide, methotrexate, and fluorouracil (CMF) in patients with operable breast cancer at risk of relapse, on the basis of three successive randomised trials and one ..
  50. ncbi Cyclophosphamide versus placebo in scleroderma lung disease
    Donald P Tashkin
    University of California at Los Angeles, Los Angeles, USA
    N Engl J Med 354:2655-66. 2006
    We conducted a double-blind, randomized, placebo-controlled trial to determine the effects of oral cyclophosphamide on lung function and health-related symptoms in patients with evidence of active alveolitis and scleroderma-related ..
  51. ncbi Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL
    Michael Pfreundschuh
    Saarland University Medical School, Homburg Saar, Germany
    Blood 104:626-33. 2004
    The combination of cyclophosphamide, doxorubicin, vincristine, and prednisone, given every 3 weeks (CHOP-21) is standard chemotherapy for aggressive lymphomas...
  52. ncbi Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab
    Nalan Akyurek
    Department of Pathology, Medical Faculty, Gazi University, Ankara, Turkey
    Cancer 118:4173-83. 2012
    ..The aim of this study was to investigate the frequency and prognostic impact of BCL2, BCL6, and MYC rearrangements in cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab (R-CHOP)-treated DLBCL cases.
  53. ncbi Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial
    Eva Ellebaek
    Department of Haematology, Center for Cancer Immune Therapy, Copenhagen University Hospital, Herlev, Herlev Ringvej 75, 2730 Herlev, Denmark
    Cancer Immunol Immunother 61:1791-804. 2012
    ..In this phase II trial, metronomic Cyclophosphamide and a Cox-2 inhibitor have been added to a DC vaccine with the intend to dampen immunosuppressive mechanisms...
  54. ncbi Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study
    Harold J Burstein
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 21:46-53. 2003
    ..We conducted a pilot study of preoperative trastuzumab and paclitaxel, followed by surgery and adjuvant doxorubicin and cyclophosphamide chemotherapy in earlier stage breast cancer.
  55. ncbi Selective depletion of CD4+CD25+Foxp3+ regulatory T cells by low-dose cyclophosphamide is explained by reduced intracellular ATP levels
    Jie Zhao
    Department of Gynecology and Obstetrics, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, The People s Republic of China
    Cancer Res 70:4850-8. 2010
    ..Although cyclophosphamide (CY) has shown promise as a drug to selectively target Treg cells with low-dose in vivo, the underlying ..
  56. ncbi Effect of preoperative chemotherapy on the outcome of women with operable breast cancer
    B Fisher
    National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA, USA
    J Clin Oncol 16:2672-85. 1998
    To determine, in women with primary operable breast cancer, if preoperative doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan; AC) therapy yields a better outcome than postoperative AC therapy, if a relationship exists between ..
  57. pmc Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide
    Urban Emmenegger
    Molecular and Cellular Biology Research, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada
    Neoplasia 13:40-8. 2011
    ..Thus, we have developed in vivo models of PC-3 human prostate cancer cells resistant to extended LDM cyclophosphamide therapy...
  58. ncbi Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer
    Andrea Fontana
    Division of Medical Oncology, Azienda USL 6 of Livorno, Italy
    Clin Cancer Res 15:4954-62. 2009
    ..v. standard dose of cyclophosphamide (CTX) immediately followed by an oral metronomic CTX regimen with celecoxib (CXB) and dexamethasone (DEX) in ..
  59. pmc Cyclophosphamide-induced cystitis increases bladder CXCR4 expression and CXCR4-macrophage migration inhibitory factor association
    Pedro L Vera
    Bay Pines VA Healthcare System, Research and Development 151, Bay Pines, Florida, USA
    PLoS ONE 3:e3898. 2008
    ..We studied whether CXCR4-MIF associations occur in rat bladder and the effect of experimental cystitis...
  60. ncbi First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULE
    Michael Untch
    Helios Klinikum Berlin Buch, Frauenheilkunde mit Geburtshilfe, Berlin, Germany
    J Clin Oncol 28:1473-80. 2010
    ..The Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial evaluated trastuzumab plus cyclophosphamide and the less cardiotoxic ..
  61. pmc Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study
    Priya P Gor
    Center for Cancer and Hematologic Disease, 1930 E Route 70, Cherry Hill, NJ 08003, USA
    Breast Cancer Res 12:R26. 2010
    b>Cyclophosphamide-based adjuvant chemotherapy is a mainstay of treatment for women with node-positive breast cancer, but is not universally effective in preventing recurrence...
  62. pmc Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial
    Edith A Perez
    Division of Hematology Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224, USA
    J Clin Oncol 26:1231-8. 2008
    ..To assess cardiac safety and potential cardiac risk factors associated with trastuzumab in the NCCTG N9831 Intergroup adjuvant breast cancer trial...
  63. ncbi Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 111:5530-6. 2008
    ..Patients received a conditioning regimen of fludarabine (30 mg/m(2) daily for 3 days), cyclophosphamide (750 mg/m(2) daily for 3 days), and rituximab (375 mg/m(2) for 1 day plus 1000 mg/m(2) for 3 days)...
  64. pmc Cyclophosphamide for ocular inflammatory diseases
    Siddharth S Pujari
    The Massachusetts Eye Research and Surgery Institution, Cambridge, Massachusetts, USA
    Ophthalmology 117:356-65. 2010
    To evaluate the outcomes of cyclophosphamide therapy for noninfectious ocular inflammation.
  65. ncbi Cyclophosphamide induces differentiation of Th17 cells in cancer patients
    Sophie Viaud
    Faculté de Médecine de l Université Paris Sud XI, Le Kremlin Bicetre, France
    Cancer Res 71:661-5. 2011
    Low doses of the alkylating agent cyclophosphamide (CTX) mediate antiangiogenic and immunostimulatory effects, leading to potent tumoricidal activity in association with various immunotherapeutic strategies...
  66. ncbi Improved survival in severe paraquat poisoning with repeated pulse therapy of cyclophosphamide and steroids
    Ja Liang Lin
    Department of Nephrology, Division of Clinical Toxicology, Chang Gung Memorial Hospital, 199, Tung Hwa North Road, Taipei, Taiwan, ROC
    Intensive Care Med 37:1006-13. 2011
    To clarify the efficacy of repeated methylprednisolone (MP) and cyclophosphamide (CP) pulse therapy and daily dexamethasone (DEX) therapy in patients with severe paraquat (PQ) poisoning.
  67. pmc Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer
    Song Yao
    Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Clin Cancer Res 16:6169-76. 2010
    There are no established genetic markers for prediction of outcomes after cyclophosphamide (CP)-containing adjuvant therapy for breast cancer...
  68. ncbi Cyclophosphamide impairs hippocampus-dependent learning and memory in adult mice: Possible involvement of hippocampal neurogenesis in chemotherapy-induced memory deficits
    Miyoung Yang
    College of Veterinary Medicine, Chonnam National University and Animal Medical Institute, Gwangju 500 757, South Korea
    Neurobiol Learn Mem 93:487-94. 2010
    b>Cyclophosphamide (CYP) is an anti-neoplastic agent as well as an immunosuppressive agent...
  69. pmc Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation
    Dan Laheru
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University School of Public Health, Baltimore, Maryland 21231, USA
    Clin Cancer Res 14:1455-63. 2008
    ..a study of two granulocyte macrophage colony-stimulating factor-secreting pancreatic cancer cell lines (CG8020/CG2505) as immunotherapy administered alone or in sequence with cyclophosphamide in patients with advanced pancreatic cancer.
  70. ncbi Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group
    Norbert Schmitz
    Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Hospital St Georg, Hamburg, Germany
    Blood 116:3418-25. 2010
    ..Treatment consisted of 6-8 courses of CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone) or etoposide plus (CHOEP)...
  71. ncbi Static and ELF magnetic fields enhance the in vivo anti-tumor efficacy of cis-platin against lewis lung carcinoma, but not of cyclophosphamide against B16 melanotic melanoma
    S Tofani
    Department of Medical Physics, Ivrea Hospital, ASL 9, 10015 TO, Ivrea, Italy
    Pharmacol Res 48:83-90. 2003
    ..cis-platin) and N,N-bis (2-chloroethyl)tetra-hydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide (cyclophosphamide). The experiment endpoint was survival time. The survival time of mice treated with cis-platin (3mg/kg i.p...
  72. ncbi A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy
    William W L Choi
    Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, Nebraska 68198 3135, USA
    Clin Cancer Res 15:5494-502. 2009
    ..Since then, new antibodies specific to germinal center B-cells have been developed, which might improve the performance of an immunostain algorithm...
  73. ncbi Rituximab plus infusional cyclophosphamide, doxorubicin, and etoposide in HIV-associated non-Hodgkin lymphoma: pooled results from 3 phase 2 trials
    Michele Spina
    Division of Medical Oncology A, National Cancer Institute, Via Pedemontana Occidentale 12, 33081, Aviano PN Italy
    Blood 105:1891-7. 2005
    ..the results of 3 prospective phase 2 trials evaluating rituximab in combination with 96-hour infusion of cyclophosphamide (187.5-200 mg/m2 per day), doxorubicin (12...
  74. ncbi Liposome-encapsulated doxorubicin in combination with standard agents (cyclophosphamide, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma: results of therapy and correlates of response
    Alexandra M Levine
    Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, CA, USA
    J Clin Oncol 22:2662-70. 2004
    ..doxorubicin (Myocet; Medeus Pharma Ltd, Herts,UK) when substituted for doxorubicin in the CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma (..
  75. ncbi Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-010
    Laura F Hutchins
    University of Arkansas for Medical Sciences, Little Rock, AR, USA
    J Clin Oncol 23:8313-21. 2005
    We evaluated the efficacy of cyclophosphamide, methotrexate, and fluorouracil (CMF) versus cyclophosphamide, doxorubicin, and fluorouracil (CAF) in node-negative breast cancer patients with and without tamoxifen (TAM), overall and by ..
  76. ncbi Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors
    Andrea Hunold
    Department of Pediatric Hematology and Oncology, University Children s Hospital, Muenster, Germany
    Pediatr Blood Cancer 47:795-800. 2006
    ..Promising response rates have recently been reported for the combination of topotecan (TOPO) and cyclophosphamide (CYC) encouraging wider application of this combination in patients with relapsed ETs...
  77. ncbi Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel
    Ian C Smith
    Department of Academic Radiology, University of Aberdeen, Foresterhill, Aberdeen, Scotland, United Kingdom
    J Clin Oncol 20:1456-66. 2002
    ..To compare the efficacy of neoadjuvant (NA) docetaxel (DOC) with anthracycline-based therapy and determine the efficacy of NA DOC in patients with breast cancer initially failing to respond to anthracycline-based NA chemotherapy (CT)...
  78. ncbi Repeated pulse of methylprednisolone and cyclophosphamide with continuous dexamethasone therapy for patients with severe paraquat poisoning
    Ja Liang Lin
    Division of Clinical Toxicology and Nephrology, Department of Medicine, Chang Gung Memorial Hospital, Lin Kou Medical Center, Chang Gung University, School of Medicine, Taipei, Taiwan, ROC
    Crit Care Med 34:368-73. 2006
    ..to <90% predictive mortality: initial pulse therapy with methylprednisolone (1 g/day for 3 days) and cyclophosphamide (15 mg/kg/day for 2 days), followed by dexamethasone 20 mg/day until Pao2 was >11...
  79. pmc Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab
    Anne M Schultheis
    University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California 90033, USA
    Clin Cancer Res 14:7554-63. 2008
    This study was designed to evaluate the associations between angiogenesis gene polymorphisms and clinical outcome in ovarian cancer patients treated with low-dose cyclophosphamide and bevacizumab.
  80. pmc Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens
    Mark E Dudley
    Surgery Branch, National Cancer Institute, NIH, Bethesda, MD 20892 1201, USA
    J Clin Oncol 26:5233-9. 2008
    ..Here, we update that study and evaluate the safety and efficacy of two increased-intensity myeloablative lymphodepleting regimens...
  81. ncbi 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen
    Susan O'Brien
    Division of Hematology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 27:5208-12. 2009
    A randomized trial of oblimersen plus fludarabine/cyclophosphamide (OBL-FC; n = 120) versus FC (n = 121) was conducted in patients with relapsed/refractory chronic lymphocytic leukemia (CLL)...
  82. ncbi Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy
    Kazuhiko Kurozumi
    Dardinger Laboratory for Neuro oncology and Neurosciences, Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210, USA
    J Natl Cancer Inst 99:1768-81. 2007
    ..We investigated oncolytic virus (OV) therapy-induced changes in tumor blood vessels and the impact of modulating tumor vasculature on the efficacy of oncolytic virus therapy...
  83. ncbi Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis
    G G Illei
    Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 10 Center Drive, Building 10, Room 9S 205, Bethesda, MD 20892, USA
    Ann Intern Med 135:248-57. 2001
    Controlled trials in lupus nephritis have demonstrated that cyclophosphamide therapy is superior to corticosteroid therapy alone...
  84. pmc Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs
    Takeshi Nakahara
    Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
    Blood 115:4384-92. 2010
    b>Cyclophosphamide (CTX), a commonly used chemotherapeutic agent can enhance immune responses. The ability of CTX to promote the proliferation of effector T cells and abrogate the function of regulatory T cells (Tregs) has been described...
  85. ncbi Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer
    Miguel Martin
    Servicio de Oncologia Medica, Hospital Universitario San Carlos, Ciudad Universitaria s n, 28040 Madrid, Spain
    J Natl Cancer Inst 100:805-14. 2008
    ..Taxanes are among the most active drugs for the treatment of metastatic breast cancer, and, as a consequence, they have also been studied in the adjuvant setting...
  86. ncbi A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients
    Jean Yves Pierga
    Institut Curie, 26 Rue d Ulm, 75005, Paris, France
    Breast Cancer Res Treat 122:429-37. 2010
    To assess anti-tumor activity of sequential epirubicin/cyclophosphamide followed by docetaxel with the randomized addition of celecoxib in HER2 negative patients or trastuzumab in HER2 positive patients...
  87. ncbi Testicular gametogenic and steroidogenic activities in cyclophosphamide treated rat: a correlative study with testicular oxidative stress
    D Ghosh
    Reproductive Endocrinology and Family Welfare Unit, Department of Human Physiology with Community Health, Vidyasagar University, Midnapore 721 102, West Bengal, India
    Drug Chem Toxicol 25:281-92. 2002
    The present work examined the changes in testicular activities in relation to testicular oxidative stress in cyclophosphamide as well as human chorionic gonadotrophin (hCG) co-treated cyclophosphamide treated Wistar strain rats...
  88. ncbi Pharmacological modulation of the micturition pattern in normal and cyclophosphamide pre-treated conscious rats
    M Andersson
    Department of Pharmacology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden
    Auton Neurosci 159:77-83. 2011
    ..of muscarinic receptors, nitric oxide and purinoceptors on the micturition pattern of conscious normal and cyclophosphamide (CYP) pre-treated rats. The micturition parameters were assessed using a metabolic cage...
  89. ncbi Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
    M E Christine Lutsiak
    Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bldg 10, Rm 8B09, Bethesda, MD 20892, USA
    Blood 105:2862-8. 2005
    ..b>Cyclophosphamide (CY) is a chemotherapeutic agent with a dose-dependent, bimodal effect on the immune system...
  90. pmc Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine
    Shiwen Peng
    Department of Otolaryngology Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA
    Cancer Immunol Immunother 62:171-82. 2013
    ..Regulatory T cells (Tregs) are cells that can dampen cytotoxic CD8(+) T-cell function. Cyclophosphamide (CTX) is a systemic chemotherapeutic agent, which can eradicate immune cells, including inhibitory Tregs...
  91. pmc Acacia Senegal gum exudate offers protection against cyclophosphamide-induced urinary bladder cytotoxicity
    Abdulaziz A Al-Yahya
    Department of Pharmacology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia
    Oxid Med Cell Longev 2:207-13. 2009
    ..GA may limit the cascading events of CYCL -induced damage, initiating a cytoprotective effect leading to structural and functional recovery of the bladder tissues...
  92. ncbi High histologic and overall response to dose intensification of ifosfamide, carboplatin, and etoposide with cyclophosphamide, doxorubicin, and vincristine in patients with high-risk Ewing sarcoma family tumors: the Bambino Gesù Children's Hospital experie
    Giuseppe Maria Milano
    Division of Pediatric Oncology, Ospedale Pediatrico Bambino Gesù IRCCS, Rome, Italy
    Cancer 106:1838-45. 2006
    ..The authors report on their results from a regimen of ifosfamide, carboplatin, and etoposide (ICE) with cyclophosphamide, doxorubicin, and vincristine (CAV) dose intensification in patients with high-risk ESFT.
  93. ncbi Long-term outcomes of idiopathic membranous nephropathy in Japanese patients treated with low-dose cyclophosphamide and prednisolone
    Masahiro Eriguchi
    Kidney Center, Matsuyama Red Cross Hospital, Matsuyama, Japan
    Nephrol Dial Transplant 24:3082-8. 2009
    Treatment with cyclophosphamide and steroids for idiopathic membranous nephropathy (IMN) is effective in Caucasian patients, but the cumulative cyclophosphamide dosage exceeds 10 g and includes steroid pulse therapy...
  94. pmc Administration of cyclophosphamide changes the immune profile of tumor-bearing mice
    Pu Liu
    Department of Pathology, Harborview Medical Center, University of Washington, Seattle, WA 98104 2499, USA
    J Immunother 33:53-9. 2010
    b>Cyclophosphamide (CTX) is often used to create a "window" for more effective therapeutic tumor vaccination...
  95. ncbi Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide
    Gaye Cunnane
    University of California San Francisco, 4150 Clement Street, San Francisco, CA 94121, USA
    Arthritis Rheum 50:1539-48. 2004
    To compare the effects of combined administration of cyclophosphamide (CYC) and CTLA-4Ig with the effects of these agents alone on the immunopathology and progression of renal damage in (NZB x NZW)F(1) (B/W) lupus-prone mice, and to ..
  96. pmc Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis
    Melanie S Joy
    Division of Nephrology and Hypertension, UNC Kidney Center, University of North Carolina School of Medicine, Chapel Hill, USA
    Br J Clin Pharmacol 74:445-55. 2012
    b>Cyclophosphamide, the precursor to the active 4-hydroxycyclophosphamide, is used in active glomerulonephritis despite limited pharmacokinetics data. The pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide were evaluated...
  97. ncbi Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?
    Nicolas Penel
    Département de Cancérologie Générale, Centre Oscar Lambret, Lille, France
    Crit Rev Oncol Hematol 82:40-50. 2012
    ..b>Cyclophosphamide is the most widely-explored agent in such an approach...
  98. ncbi The chemistry of the metabolites of cyclophosphamide
    S M Ludeman
    Duke Comprehensive Cancer Center and Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
    Curr Pharm Des 5:627-43. 1999
    This is primarily an overview of the spontaneous (non-enzymatic) chemistry of the metabolites of cyclophosphamide, viz...
  99. ncbi Inhibitory action of melatonin on H2O2- and cyclophosphamide-induced DNA damage
    R De Salvia
    Centro di Genetica Evoluzionistica, CNR, Universita La Sapienza, Roma, Italy
    Mutagenesis 14:107-12. 1999
    ..is able to modulate chromosome damage (chromosomal aberrations and sister chromatid exchanges) induced by cyclophosphamide. Conversely, its involvement in modulating oxidative processes, thereby reducing DNA damage, is less clear...
  100. ncbi Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma
    J H Burton
    Department of Clinical Sciences, Animal Cancer Center, Colorado State University, Fort Collins, CO 80523, USA
    J Vet Intern Med 25:920-6. 2011
    ..The effects of metronomic chemotherapy on Treg and tumor angiogenesis in dogs has not been investigated previously...
  101. pmc Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma
    Ihid C Leao
    Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Clin Transl Sci 1:228-39. 2008
    ..evaluated for recognition by vaccine-induced T cells from mice treated with vaccine in sequence with low-dose cyclophosphamide (CY) and an anti-CD25 IL-2Ralpha monoclonal antibody (PC61)...

Research Grants74

  1. Molecular Mechanism of Immune Therapy for Bone Marrow Failures
    Pearlie K Epling-Burnette; Fiscal Year: 2013
    ..by clinical improvement with immunosuppressive therapy (IST) such as low-dose methotrexate (MTX), low- dose cyclophosphamide (CY) or cyclosporine A (CyA) and, in the case of aplastic anemia and MDS, T cell depletion with anti-..
  2. Anti-Fibrotic Therapy for Scleroderma/SSc
    Latha Paka; Fiscal Year: 2010
    ..Immunosuppressive agents such as corticosteroids and cyclophosphamide have demonstrated marginal efficacy, or have side effects...
  3. Bone Marrow Transplantation for Hematologic Malignancies using Novel Radioimmunot
    John M Pagel; Fiscal Year: 2013
    ..total body irradiation (TBI) and Fludarabine (FLU) in a preclinical murine haploidentical HCT model employing cyclophosphamide (CY) post-transplant graft-vs-host disease prophylaxis...
  4. Novel Hematopoietic Conditioning Agents for Treatment of Hematological Diseases
    Olga B Chernova; Fiscal Year: 2010
    ..Prior to transplant, patients receive a conditioning regimen of cytotoxic drugs (e.g. cyclophosphamide/busulfan) and/or total body irradiation in order to suppress the immune system and, in the case of ..
  5. Anti- IL5 therapy for Churg-Strauss Syndrome: a double blind randomized, placebo-
    Michael E Wechsler; Fiscal Year: 2010
    ..CSS therapies, corticosteroids and cytotoxic agents such as cyclophosphamide and azathioprine, have multiple systemic side effects, do not offer the potential for long-term cure, and ..
  6. Yale Autoimmunity Center of Excellence
    Kevan C Herold; Fiscal Year: 2013
    ..NOD mouse, immunization with a similar fusion molecule attenuated spontaneous disease, disease induced with cyclophosphamide, and the adoptive transfer of disease...
  7. Transplantation tolerance and immune function following mTOR inhibition.
    Jonathan D Powell; Fiscal Year: 2013
    ..principles in the choice of preparative regimen with the addition of dose escalation of post transplant cyclophosphamide to further reduce alloreactive T cells that could contribute to rejection or GVHD...
  8. AUTOIMMUNITY CENTER OF EXCELLENCE
    David Wofsy; Fiscal Year: 2013
    ..Two concept proposals are presented. Protocol 1 is a phase Ib/lla trial of anti-CD20 plus cyclophosphamide (IVC) as induction therapy in patients with active lupus nephritis...
  9. Therapeutic Value of Fish Oil Rx on SLE and Bone Loss in Mice
    GABRIEL J J FERNANDES; Fiscal Year: 2012
    ..oil;Specific aim 3 is to determine the interaction of OMACOR n-3 fatty acids along with immunosuppressive cyclophosphamide and methylprednisolone drug therapy after the onset of SLE in controlling renal disease and bone loss in MRL/..
  10. Manipulation of Host Angiogenesis as a Therapeutic Strategy against Invasive Pulm
    Dimitrios P Kontoyiannis; Fiscal Year: 2010
    ..To that end, we will use two murine models of IA following induction of neutropenia with cyclophosphamide: (1) An acute pulmonary model, in which infection is established by intranasal instillation of a concentrated ..
  11. Systemic Chemotherapy of Melanoma: NMR Studies of Lonidamine &N-Mustard Activity
    Jerry D Glickson; Fiscal Year: 2013
    ..enhancements of activity at acidic pHi values but perhaps with lower toxicity, LPAM will be compared with cyclophosphamide, chlorambucil and bendamustine under single and multidose administration...
  12. Anti-Fibrotic Therapy for Scleroderma/SSc
    Latha Paka; Fiscal Year: 2013
    ..Immunosuppressive agents such as corticosteroids and cyclophosphamide have demonstrated marginal efficacy, or have side effects...
  13. Measles Virotherapy and radiovirotherapy in the Treatment of recurrent gliomas
    Evanthia Galanis; Fiscal Year: 2013
    ..of the beta and gamma emitter 131I (radiovirotherapy);and combining measles virus derivatives with cyclophosphamide, an agent that has been shown to suppress anti-viral innate and adaptive immunity, and increase viral ..
  14. 1H MRI based nanosensors for imaging tumor oxygenation
    Vikram D Kodibagkar; Fiscal Year: 2010
    ..Effect of combination chemotherapy consisting of metronomic cyclophosphamide and will be studied on tumor oxygenation parameters such as baseline pO2, HF5 and response to hyperoxia with ..
  15. RCT of GnRH-a for ovarian protection during CYC therapy for rheumatic disease
    WILLIAM J MC CUNE; Fiscal Year: 2012
    ..agonist (GnRH-a) reduces ovarian injury versus placebo in women of reproductive age being treated with cyclophosphamide for severe rheumatic diseases...
  16. Trial of mesna to prevent doxorubicin-induced plasma protein oxidation and TNFa r
    Jeffrey A Moscow; Fiscal Year: 2012
    ..regimens to prevent hemorrhagic cystitis associated with the alkylating agents ifosfamide and high-dose cyclophosphamide, and is commonly coincidentally co-administered with anthracyclines without affecting cancer therapy outcomes...
  17. Taste and Cyclophosphamide in Mice
    Eugene R Delay; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Cyclophosphamide (CYP), widely used to treat cancer, will serve as a prototypical agent to study novel questions about how chemotherapy drugs disrupt taste, how cell populations within taste buds are ..
  18. THE ROLE OF METABOTROPIC GLUTAMATE RECEPTOR 5 (MGLUR5) IN BLADDER PAIN
    HING HUNG HENRY LAI; Fiscal Year: 2013
    ..1: To test the hypothesis that spinal mGluR5 modulates bladder hyperalgesia in mouse models of bladder pain (cyclophosphamide cystitis, bacterial cystitis)...
  19. 1H NMR STUDIES OF NON-HODGKINS LYMPHOMA
    Jerry D Glickson; Fiscal Year: 2012
    ..have examined the response to multiple clinically relevant therapies including: combination chemotherapy with Cyclophosphamide, Hydroxydoxorubicin, Oncovin and Prednisone (CHOP), CHOP plus Bryostatin 1 (CHOPB), Rituximab alone, ..
  20. A Novel Testicular Germ Cell Maturation Model for Fertility Preservation in Pre-p
    Kirk C Lo; Fiscal Year: 2012
    ..first part of the study, we will administer different concentrations of the commonly used chemotherapy agent, cyclophosphamide, to the mice with the testis transplant to study the effects of this chemotherapy on human pre-pubertal ..
  21. Outcomes Research in Rheumatic Diseases
    Dinesh Khanna; Fiscal Year: 2013
    ..oral cyclophosphamide in 150 patients with active SSc-ILD. 2...
  22. Immune Cell Carriers for the Delivery of Oncolytic Viruses to Metastatic Tumors
    Richard G Vile; Fiscal Year: 2013
    ..To address the critical issue of pre-existing immunity to the virus, we demonstrated that careful dosing of cyclophosphamide can modulate levels of neutralizing antibody to enhance systemic delivery (Clin Canc Res 14:259) and that the ..
  23. Anti IL5 and Churg Strauss Syndrome: a double blind, placebo controlled trial
    Michael E Wechsler; Fiscal Year: 2013
    ..CSS therapies (e.g. corticosteroids, cyclophosphamide, azathioprine) have multiple side effects, do not offer potential for long-term cure, and often fail to yield ..
  24. MOCSLID-DCC
    Robert M Elashoff; Fiscal Year: 2012
    ..the first randomized controlled trial to demonstrate that SSc-ILD responds to a one- year treatment with oral cyclophosphamide (CYC) with improvements in pulmonary function, dyspnea, skin disease, and health-related quality of life (..
  25. Radiation Protectors and Radiation Therapy Coupled Chemoprevention
    David J Grdina; Fiscal Year: 2013
    ..micro lung metastases treated with ionizing radiation and an alkylating-chemotherapeutic agent such as cyclophosphamide. Using the Hprt mutation assay, we will assess the anti-mutagenic effectiveness of TCC agents in MLL-ELL ..
  26. Novel Immunotherapeutic Approaches and Tools Utilizing Allogeneic T Cells
    HEATHER JILL SYMONS; Fiscal Year: 2013
    ..We have used high dose, post-transplantation cyclophosphamide (Cy) in two existing clinical trials to enable partially HLA-mismatched alloSCT after nonmyeloablative ..
  27. Combination Therapy in B-Chronic Lymphocytic Leukemia
    Neil E Kay; Fiscal Year: 2012
    ..trial in patients with previously untreated B-CLL for which we administered the combination pentostatin (P), cyclophosphamide (C) and rituximab (R) (PCR)...
  28. Pharmacogenetics of Tamoxifen and Chemotherapies and Risk of Contralateral Breast
    Jane C Figueiredo; Fiscal Year: 2010
    ..CYP3A5, SULT1A1, UGT2B15) and drugs commonly used in polychemotherapy regimens for breast cancer including: cyclophosphamide (i.e., CYP3A5, GSTM1, GSTP1, GSTT1);anthracyclines (i.e...
  29. Gene Therapy and Radiation Therapy for Prostate Cancer
    Svend O Freytag; Fiscal Year: 2013
    ..In specific aim 2, we will test the hypothesis that cyclophosphamide (CP) can be combined safely with replication-competent adenovirus-mediated suicide and IL-12 gene therapy and ..
  30. Innovative Device to Improve Safety of Preparing and Administering Chemotherapy
    Prasad Sunkara; Fiscal Year: 2013
    ..be delivered to patients) in multiple pharmacy settings using two well established chemotherapy marker drugs: cyclophosphamide and fluorouracil...
  31. Maximizing Memory T Cell Responses by Matured Post Chemotherapy Dendritic Cells
    Mark P Rubinstein; Fiscal Year: 2012
    ..We have made the novel observation that treatment with the anti-cancer drug cyclophosphamide induces a marked expansion of dendritic cells, which play central roles in shaping the immune responses ..
  32. Improving the Efficacy of Dendritic Cell Vaccines
    JACQUES F BANCHEREAU; Fiscal Year: 2010
    ..the distinct T cell differentiation they induce, 3) eliminate suppressor T cells by treatment with cyclophosphamide (CPA) prior to vaccination with DCs, 4) study myeloma to gain key information on the host response to DCs ..
  33. Induction of Donor Tolerance in Renal Transplants
    Suzanne T Ildstad; Fiscal Year: 2012
    ..We have developed a nonmyeloablative conditioning regimen with 200 cGy TBI/fludarabine/cyclophosphamide/MMF/prograf to avoid the toxicity of conditioning...
  34. Phase I/II Randomized Tiral of Adoptive Lymphocyte Transfer in Ovarian Cancer
    George Coukos; Fiscal Year: 2013
    ..anti-tumor activity and the development of pharmacologic interventions to attenuate them, such as metronomic cyclophosphamide chemotherapy, may potentiate tumor immunity, although its impact on effector T cells is unknown...
  35. Vaccine-Dac/Bev Combinatorial Therapy in Ovarian Cancer
    George Coukos; Fiscal Year: 2012
    ..weak vaccine (immature DCs pulsed with tumor lysate supernatants) combined with VEGF blockade and metronomic cyclophosphamide. Here we propose a phase I/II clinical study that will enable us to start carefully testing the hypothesis ..
  36. Synthesis, Structure and Repair of DNA Interstrand Crosslinks
    ORLANDO D SCHARER; Fiscal Year: 2013
    PROJECT SUMMARY A number of clinically important antitumor agents such as cisplatin, cyclophosphamide (a nitrogen mustard) or carmustine (BCNU, a chloro ethyl nitroso urea) form DNA interstrand crosslinks (ICLs) as key cytotoxic lesions...
  37. MOCSLID-CCC
    Donald P Tashkin; Fiscal Year: 2012
    ..the first randomized controlled trial to demonstrate that SSc-ILD responds to a one year treatment with oral cyclophosphamide (CYC) with improvements in pulmonary function, dyspnea, skin disease, and health-related quality of life (..
  38. Effects of chemotherapeutic agents on learning and memory in mice
    ELLEN ANN WALKER; Fiscal Year: 2013
    ..Specifically, we will treat male and female mice with multiple doses of cyclophosphamide, doxorubicin, 5-fluorouracil, methotrexate, tamoxifen, and docetaxel at various time points to measure ..
  39. Optimizing Measles Virotherapy in the Treatment of Ovarian Cancer
    Kah Whye Peng; Fiscal Year: 2012
    ..for radiovirotherapy;use of infected cell carriers for viral delivery;and, combining the measles virus with cyclophosphamide, an agent with immunosuppressive and antitumor properties...
  40. Novel Rho Kinase Inhibitor for Systemic Sclerosis
    Susan C Wright; Fiscal Year: 2013
    ..b>Cyclophosphamide is the main treatment for progressing skin involvement and is effective in early stages of the disease but ..
  41. Targeted Treatment of Recurrent Small Cell Lung Cancer with Anti-AbnV2 Antibodies
    Roy H L Pang; Fiscal Year: 2013
    ..Abner significantly slows growth, but this growth is completely impaired when antibody treatment follows cyclophosphamide. Our data indicate AbnV2R expression is a feature common to all, or most, SCLC and that AbnV2R is a surface ..
  42. Dissecting the mechanisms of immune tolerance within the pancreatic tumor's micro
    Lei Zheng; Fiscal Year: 2013
    ..with vaccine given in sequence with either a single intravenous dose or daily metronomic oral doses of cyclophosphamide (Cy) as approaches for inhibiting Tregs...
  43. Combination Therapies for Cancer Treatment
    David J Waxman; Fiscal Year: 2013
    ..tyrosine kinase inhibitor axitinib and the liver cytochrome P450-activated anti-cancer prodrug cyclophosphamide. The major aims of this proposal are: 1) to elucidate the mechanism whereby anti-angiogenic drug treatment ..
  44. Predictors of ovarian failure after chemotherapy in young breast cancer patients
    HUI CHUN IRENE SU; Fiscal Year: 2013
    ..Breast cancer patients with drug metabolizing enzyme polymorphisms resulting in higher cyclophosphamide exposure are more likely to develop ovarian failure after cyclophosphamide-based adjuvant chemotherapy;3)...
  45. MIF: a pro-inflammatory cytokine as a novel target to reduce bladder inflammation
    Pedro L Vera; Fiscal Year: 2013
    ..will be used to examine changes in MIF-mediated signaling during a well-established model of cystitis (cyclophosphamide) in mice...
  46. Antibody Neutralization of Therapeutic Viruses
    Stephen J Russell; Fiscal Year: 2012
    ..Specific aims are as follows: Aim 1. Develop a clinically viable strategy using cyclophosphamide in combination with measles booster vaccination to reduce the plasma concentration of neutralizing anti-..
  47. Pharmacogenetics of Cyclophosphamide ADRs in
    Jeannine S McCune; Fiscal Year: 2012
    ..The long range goal of this work is to improve failure-free survival in children receiving conventional dose cyclophosphamide (CY) by personalizing cancer treatment and/or CY doses, either by pharmacogenetics (Aim 1) or by ..
  48. Origins and Functions of Mammalian Female Germline Stem Cells
    JONATHAN LEE TILLY; Fiscal Year: 2013
    ..transplantation (BMT) rescues oocyte production in adult mice rendered sterile by chemotherapy (busulfan plus cyclophosphamide) or a genetic mutation {Atm gene knockout)...
  49. Systemic cancer treatment and subsequent cognitive decline
    Francine Grodstein; Fiscal Year: 2013
    ..including: (i) 5-FU, as this agent crosses the blood brain barrier more readily than many others;and (ii) cyclophosphamide, the backbone of breast cancer treatment during the period our breast cancer survivors were diagnosed (with ..
  50. Transport of Large Molecules and Viral Vectors in Tumors: Effects of Cytotoxic an
    Yves Boucher; Fiscal Year: 2013
    ..targeted with endothelial cell targeting agents (anti-integrin 14 or 15 blocking antibodies) or cytotoxics (cyclophosphamide, docetaxel) that target both endothelial and cancer cells...
  51. Potentiating Adoptive T Cell Therapy by Immunomodulation
    Cassian Yee; Fiscal Year: 2009
    ..We propose to identify in a Phase I, dose-finding study, a cyclophosphamide conditioning regimen pre- infusion and a dose of IL-2 post-infusion that is safe and that supports the in ..
  52. Pharmacogenomics of Breast Cancer Adjuvant Chemotherapy
    Richard M Weinshilboum; Fiscal Year: 2011
    ..One arm involved treatment with "standard" chemotherapy consisting of 5-flurouracil-epirubicin-cyclophosphamide (FEC) plus docetaxel, and the other involved FECdocetaxel plus gemcitabine...
  53. Pharmacogenetics in children with high-risk neuroblastoma
    Jeannine S McCune; Fiscal Year: 2013
    ..survival in children with newly-diagnosed high-risk neuroblastoma by personalizing cancer treatment and/or cyclophosphamide (CY) doses by pharmacogenetics...
  54. Cyclophosphamide modified GM-CSF pancreatic tumor vaccine + listeria-mesothelin
    Dung T Le; Fiscal Year: 2013
    ..responses and clinical responses in patients with metastatic PDA treated with immunomodulatory doses of cyclophosphamide (Cy) in sequence with a priming allogeneic GM-CSF transfected pancreatic tumor vaccine (GM-CSF vaccine) ..
  55. Myeloablative T- Replete Haploidentical PBSCT for Patients Without MRD or MUD
    Asad Bashey; Fiscal Year: 2013
    ..donor) hematopoietic cell transplants (haplo-HCT) using T-cell-replete marrow grafts and post- transplant cyclophosphamide (PTCy), have been shown to produce high rates of engraftment and low treatment related mortality (TRM) when ..
  56. MECHANISMS OF GVHD PREVENTION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE
    EDUS HOUSTON WARREN; Fiscal Year: 2013
    ..by applicant): Emerging clinical data in the HLA-matched setting suggest that high-dose post-transplant cyclophosphamide (Cy) given as a single agent is effective in preventing both acute and chronic graft-versus-host disease (..
  57. IGF1R gene 3'UTR variants in high-risk pediatric neuroblastoma
    Andrei Thomas-Tikhonenko; Fiscal Year: 2013
    ..analysis and compare and contrast responses of rs3833015 and rs374251 tumors to conventional therapeutics (cyclophosphamide and topotecan) and IGF1R inhibitors...
  58. Clinical pharmacology of cyclophosphamide in pediatric medulloblastoma patients
    Michael B Tagen; Fiscal Year: 2010
    ..b>Cyclophosphamide is an alkylating agent that is used as part of the chemotherapy regimen for these tumors following surgery ..
  59. The PI3K/PTEN/AKT Signal Transduction Cascade in Breast Cancer
    Ana M Gonzalez Angulo; Fiscal Year: 2010
    ..response to preoperative taxane (paclitaxel or docetaxel) and 5-fluoruracil, doxorubicin/epirrubicin, and cyclophosphamide (paclitaxel-FA/EC) chemotherapy, and (3) To determine whether a therapeutic intervention targeting the PI3K/..
  60. Use of Diversity Outbred Mice to rapidly identify drug toxicity loci
    Gary A Churchill; Fiscal Year: 2010
    ..genes responsible for the myelosuppressive effects of three cancer chemotherapeutic drugs, doxorubicin, cyclophosphamide, and docetaxel...
  61. Combinatorial targeting of melanoma initiating cells
    Soldano Ferrone; Fiscal Year: 2012
    ..melanoma initiating cells (MMIC) and tumor-associated pericytes, in combination with continuous low dose cyclophosphamide, i.e. metronomic chemotherapy...
  62. Anticancer Drug Pharmacology in Very Young Children
    Clinton F Stewart; Fiscal Year: 2013
    ..clinical pharmacokinetic (PK), pharmacogenetic, and pharmacodynamic (PD) studies of methotrexate (MTX), cyclophosphamide (CTX), and topotecan (TPT) as part of a clinical protocol that treats infants and young children with ..
  63. GLUTATHIONE AND RESISTANCE TO CANCER CHEMOTHERAPY
    Owen Griffith; Fiscal Year: 2000
    DESCRIPTION: (Applicant's Abstract) Bifunctional alkylating agents (e.g., melphalan, cyclophosphamide, chlorambucil) and platinum antitumor compounds (e.g. cisplatin, carboplatin) are used to treat a wide range of human malignancies...
  64. ACTIVE SPECIFIC IMMUNOTHERAPY IN MAN--A MURINE MODEL
    Barry Kahan; Fiscal Year: 1992
    ..focusing, was demonstrated to potentiate the therapeutic effects of a variety of immunostimulants: (1) cyclophosphamide (20 mg/kg IP once), (2) continuous intrasplenic (IV x3) infusion of Interleukin-2 (120 U/day x7 days), (3) ..
  65. Prediction of Lupus Outcome by Gene Expression Patterns
    Robert Winchester; Fiscal Year: 2006
    ..Second, whether CellCept will prove to be efficacious in a different gene expression subset, suggesting it could be used in these cases as a less toxic alternative to Cytoxan. ..
  66. MicroRNAs Regulating The Fanconi Anemia-BRCA Pathway
    Toshiyasu Taniguchi; Fiscal Year: 2009
    DESCRIPTION (provided by applicant): DNA-crosslinking agents such as cisplatin, carboplatin, cyclophosphamide, mitomycin C and melphalan are widely-used drugs for treatment of cancers including leukemia, lymphoma, and myeloma...
  67. MECHANISM OF CYCLOPHOSPHAMIDE TOXICITY
    JAMES KEHRER; Fiscal Year: 1999
    b>Cyclophosphamide (CP) is a widely used alkylating agent which must be bioactivated to exert its therapeutic and toxic effects...
  68. Oral Chemotherapy in AIDS-related NHL in Uganda & Kenya
    Scot Remick; Fiscal Year: 2003
    An oral-based combination chemotherapy regimen, consisting of lomustine (CCNU), etoposide (VP-16) cyclophosphamide and procarbazine, has been specifically developed for patients with AIDS-related non-Hodgkin's lymphoma (NHL)...
  69. Syrian Hamster as a Permissive Model for Testing Anti-Adenovirus Drugs
    William Wold; Fiscal Year: 2007
    ..Of great interest, immunosuppression of the hamsters using cyclophosphamide (CP) leads to much higher levels of replication of the viruses...
  70. TUMOR MARKERS TO PREDICT TREATMENT RESPONSE
    Lynn Dressler; Fiscal Year: 2005
    ..trial proposed by the CALGB, entitled," A Randomized Trial of Adjuvant Chemotherapy with Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil- "CMF" or Cyclophosphamide and Doxorubicin -"AC" versus Capecitabine in Women ..
  71. LUNG TOXIC INTERACTIONS INVOLVING THERAPEUTIC DRUGS
    JAMES KEHRER; Fiscal Year: 1991
    ..Bleomycin and cyclophosphamide (CP) will be used since they have been used clinically in combination and each has been shown to produce lung ..
  72. Endothelial reactivity and nitric oxide synthetase activity in the ALMS (Aspreva
    Robert Clancy; Fiscal Year: 2009
    ..for the proposed study is that the immunomodulatory drug mycophenolate mofetil (MMF), in contrast to cyclophosphamide or azathioprine, interferes with pterin availability to NOS2...
  73. ORAL CYCLOPHOSPHAMIDE VS ORAL PLACEBO IN SSC ALVEOLITIS
    Daniel Furst; Fiscal Year: 2001
    ..Uncontrolled series suggest that cyclophosphamide (CYC) may stabilize or improve lung function in SSc patients with active alveolitis...
  74. ORAL CYCLOPHOSPHAMIDE VS ORAL PLACEBO IN SSC ALVEOLITIS
    Dean Schraufnagel; Fiscal Year: 2003
    ..Uncontrolled series suggest that cyclophosphamide (CYC) may stabilize or improve lung function in SSc patients with active alveolitis...